Savolitinib
Savolitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target hepatocyte growth factor receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 2 | 5 | 4 | — | — | 11 | ||
| Neoplasms | D009369 | C80 | 6 | 1 | 2 | — | — | 9 | |
| Renal cell carcinoma | D002292 | — | 4 | 2 | — | — | 6 | ||
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Urologic neoplasms | D014571 | C64-C68 | — | — | 1 | — | — | 1 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | 1 | — | — | 1 |
| Neoplasms by site | D009371 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
| Glioma | D005910 | EFO_0000520 | 1 | — | — | — | — | 1 | |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Medulloblastoma | D008527 | 1 | — | — | — | — | 1 | ||
| Diffuse intrinsic pontine glioma | D000080443 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SAVOLITINIB |
| INN | savolitinib |
| Description | Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21 |
Identifiers
| PDB | — |
| CAS-ID | 1313725-88-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3334567 |
| ChEBI ID | — |
| PubChem CID | 68289010 |
| DrugBank | DB12048 |
| UNII ID | 2A2DA6857R (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MET
MET
Organism
Homo sapiens
Gene name
MET
Gene synonyms
NCBI Gene ID
Protein name
hepatocyte growth factor receptor
Protein synonyms
HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met
Uniprot ID
Mouse ortholog
Met (17295)
hepatocyte growth factor receptor (P16056)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 704 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more